Skip to main content
Fig. 8 | Clinical Epigenetics

Fig. 8

From: ZMYND10, an epigenetically regulated tumor suppressor, exerts tumor-suppressive functions via miR145-5p/NEDD9 axis in breast cancer

Fig. 8

ZMYND10 decreased the expression of NEDD9 via altering the miR-145-5p level. a Predicted duplex formation between human miR-145-5p and human wild type (WT) NEDD9 3′UTR. b The expression of miR145-5p was examined via qPCR in MDA-MB231 and SK-BR-3 cells transfected with vector or ZMYND10 plasmid. c Luciferase assay was performed to detect the regulation of miR-145-5p on WT and mutant of NEDD9-3′UTR in MDA-MB231and SK-BR-3 cells transfected with miR-NC or miR145-5p inhibitor oligo. d qPCR analysis for miR145-5p expression in MDA-MB231 and SK-BR-3 cells with ZMYND10+miR-NC or ZMYND10+ miR145-5p inhibitor. e qPCR analysis for NEDD9 expression in MDA-MB231 and SK-BR-3 cells with ZMYND10+miR-NC or ZMYND10+miR145-5p inhibitor. f Western blot assay was performed to detect the protein levels of NEDD9 in MDA-MB231 and SK-BR-3 cells transfected with p-EGFPc2, p-EGFPc2+ miR145-5p inhibitor, ZMYND10, and ZMYND10+ miR145-5p inhibitor. *p < 0.05;**p < 0.01; ***p < 0.001

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us